（文章来源：证券日报） 证券日报网讯 2月4日，晶华微在互动平台回答投资者提问时表示，公司目前经营正常，已严格按照相 关法律法规要求披露2025年度业绩预告，公司相关信息均以在指定媒体披露的公告为准。 ...

证券日报网讯2月4日，晶华微在互动平台回答投资者提问时表示，截至2026年1月30日，公司股东人数 为7678户。 ...

证券日报网讯1月27日，晶华微在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东人数 为7884户。 ...

1月26日，晶华微（维权）跌1.47%，成交额3526.93万元。两融数据显示，当日晶华微获融资买入额 274.04万元，融资偿还207.94万元，融资净买入66.10万元。截至1月26日，晶华微融资融券余额合计 3866.41万元。 分红方面，晶华微A股上市后累计派现998.40万元。 机构持仓方面，截止2025年9月30日，晶华微十大流通股东中，华商上证科创板综合指数增强A （023897）退出十大流通股东之列。 责任编辑：小浪快报 融券方面，晶华微1月26日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，杭州晶华微电子股份有限公司位于浙江省杭州市滨江区长河街道长河路351号4号楼5层A座 501室，成立日期2005年2月24日，上市日期2022年7月29日，公司主营业务涉及高性能模拟及数模混合 集成电路的研发与销售,主要产品包括医疗健康SoC芯片、工业控制及仪表芯片、智能感知SoC芯片等。 主营业务收入构成为：工业控制及仪表芯片41.56%，医疗健康SoC芯片34.45%，智能感知So ...

Core Viewpoint - The company, Hangzhou Jinghua Microelectronics Co., Ltd., has released its preliminary performance forecast for the year 2025, indicating a significant increase in revenue but a larger net loss compared to the previous year [2][4]. Performance Forecast - The company expects to achieve an operating income of between 170 million and 180 million yuan in 2025, representing a year-on-year growth of 26.07% to 33.49% [2]. - The projected net loss attributable to the parent company is estimated to be between 55 million and 30 million yuan, which is an increase in loss of 19.73 million to 44.73 million yuan compared to the previous year, reflecting a year-on-year increase in loss of 192.11% to 435.54% [2]. - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is expected to be between 98 million and 70 million yuan, indicating an increase in loss of 42.24 million to 70.24 million yuan compared to the previous year, with a year-on-year increase in loss of 152.15% to 253.02% [2]. Previous Year Performance - In 2024, the company reported an operating income of 134.85 million yuan, with a total profit of -10.27 million yuan and a net profit attributable to the parent company of -10.27 million yuan [4]. Reasons for Performance Changes - The company acquired 100% of Shenzhen Jinghua Zhixin Microelectronics Co., Ltd. for 200 million yuan in December 2024, with part of the payment contingent on performance targets [5]. - Due to market changes, intensified competition, and delays in new product launches, the operational performance of Jinghua Zhixin fell short of expectations, leading to indications of goodwill impairment and the need to recognize some impairment losses [5]. - Despite short-term challenges, the acquisition has effectively expanded the company's business scale and opened new market areas [6]. Strategic Adjustments - The company is focusing on resource integration, promoting new products, and enhancing cost control to improve operational efficiency and profitability [7]. - The company has increased its product layout efforts, with R&D expenses expected to reach approximately 97 million yuan in 2025, a year-on-year increase of about 33% [7].

晶华微(688130.SH)发布2025年年度业绩预告，预计2025年度实现归属于母公司所有者的净利润为-5,500 万元至-3,000万元，与上年同期相比，亏损将增加1,972.99万元至4,472.99万元，同比增亏192.11%至 435.54%。 ...

Core Viewpoint - Jinghua Micro (688130.SH) forecasts a net loss attributable to shareholders of the parent company for the year 2025, expected to be between -55 million and -30 million yuan, indicating a significant increase in losses compared to the previous year [1] Financial Performance - The projected net loss for 2025 represents an increase of 19.72 million to 44.73 million yuan compared to the same period last year [1] - The year-on-year increase in losses is estimated to be between 192.11% and 435.54% [1]

报告期内，公司持续加大产品布局力度，丰富产品矩阵，研发投入、股份支付费用的增加等因素导致公 司经营费用同比增加。2025年度，公司研发费用约9,700万元，同比增长约33%，公司在研芯片项目数 量较去年同期增长约37%，流片次数提升超110%，将为公司长期发展储备增长动力。 公司将通过加速资源整合与优化、推进新品推广、强化精细化成本管控等，着力提升公司及晶华智芯的 运营效率与盈利能力。 格隆汇1月21日丨晶华微（维权）(688130.SH)公布，公司财务部门初步测算，预计2025年度实现营业收 入17,000万元至18,000万元，较上年同期增长26.07%至33.49%。公司预计2025年度实现归属于母公司所 有者的净利润为-5,500万元至-3,000万元，同比增亏192.11%至435.54%。公司预计2025年度实现归属于 母公司所有者的扣除非经常性损益的净利润为-9,800万元至-7,000万元，同比增亏152.15%至253.02%。 ...

Financial Projections - The company expects to achieve operating revenue of between 170 million and 180 million yuan in 2025, representing a year-on-year growth of 26.07% to 33.49%[3] - The projected net loss attributable to the parent company for 2025 is estimated to be between 55 million and 30 million yuan, an increase in loss of 19.73 million to 44.73 million yuan compared to the previous year, reflecting a year-on-year increase in loss of 192.11% to 435.54%[3] - The company anticipates a net loss of between 98 million and 70 million yuan after deducting non-recurring gains and losses, which is an increase in loss of 42.24 million to 70.24 million yuan year-on-year, indicating a year-on-year increase in loss of 152.15% to 253.02%[3] - In 2024, the company achieved operating revenue of 134.85 million yuan, with a net loss of 10.27 million yuan attributable to the parent company[4] Acquisitions and Investments - The company acquired 100% equity of Shenzhen Jinghua Zhixin Microelectronics Co., Ltd. for 200 million yuan, with 60 million yuan being conditional payment based on performance targets[5] - The company has increased its R&D expenses to approximately 97 million yuan in 2025, a year-on-year increase of about 33%, with the number of chip projects under research growing by approximately 37%[6] Product Development and Sales - The company successfully introduced new products such as blood glucose meter chips and pressure/temperature sensor chips, leading to improved quarterly sales performance[6] - The company is focusing on resource integration, new product promotion, and cost control to enhance operational efficiency and profitability[6] Regulatory and Compliance Issues - The company is currently under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[7] - The financial data provided is preliminary and has not been audited, with the final figures to be disclosed in the audited annual report for 2025[8]

证券日报网讯12月17日，晶华微在互动平台回答投资者提问时表示，公司主营业务收入以境内销售为 主，2024年度境外销售收入占比为0.75%。公司有少量产品出口欧盟国家，业务占比相对较少。 ...